Basic Information
RNALocate ID: RLID:11004047
RNA Symbol: hsa-miR-629-5p
Localization: Exosome
RNA Information
RNA Name: hsa-miR-629-5p
RNA ID: miRBase:MIMAT0004810
RNA Category: miRNA
Species: Homo sapiens
Sequence:
Localization Information
PubMed ID: 25330373
Tissue/Cell Line: Colon cancer cell line (LIM1863)
Method: qRT-PCR|RNA sequencing
Description: To assess whether some miRNAs are specifically sorted into EVs we conducted a miRNA-enrichment analysis for A33-Exos, EpCAM-Exos and sMVs. MiRNAs with <2 fold changes relative to CL miRNAs were filtered out, yielding 63 miRNAs for comparison (Table 2). Data are collected from Table 2.
Other Subcellular Localization
RNALocate ID Localization Tissue/Cell line PubMed ID
RLID:01002687 Cytoplasm Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) 24918059
RLID:01002688 Mitochondrion Cell line (HEK-293|HeLa) 22984580
RLID:01002689 Nucleus Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) 24918059
RLID:11004045 Exosome Plasma 23663360
RLID:11004046 Exosome K562 cells 24460325
RLID:11004048 Microvesicle Plasma 23077538
RLID:11004049 Microvesicle Seminal plasma 23539611
RLID:11004050 Microvesicle Follicular fluid 23666971
RLID-D:11000704 Microvesicle Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine
RLID-D:11001579 Exosome Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine
ncRNA Disease Information
Resource RNA Symbol Disease Link
MNDR hsa-miR-629-5p Multiple sclerosis chronic progressive MNDR-E-MI-64183
MNDR hsa-miR-629-5p Large cell neuroendocrine cancer MNDR-E-MI-64184
MNDR hsa-miR-629-5p Small intestinal neuroendocrine tumor MNDR-E-MI-64185
MNDR hsa-miR-629-5p Uterine corpus endometrial carcinoma MNDR-E-MI-64186
MNDR hsa-miR-629-5p Estrogen-receptor positive breast cancer MNDR-E-MI-64187
MNDR hsa-miR-629-5p Estrogen-receptor negative breast cancer MNDR-E-MI-64188
MNDR hsa-miR-629-5p Progesterone-receptor positive breast cancer MNDR-E-MI-64189
MNDR hsa-miR-629-5p Progesterone-receptor negative breast cancer MNDR-E-MI-64190
MNDR hsa-miR-629-5p Her2-receptor positive breast cancer MNDR-E-MI-64191
MNDR hsa-miR-629-5p Breast cancer luminal MNDR-E-MI-64192
MNDR hsa-miR-629-5p Precursor cell lymphoblastic leukemia-lymphoma MNDR-E-MI-64193
MNDR hsa-miR-629-5p B cell acute lymphoblastic leukemia MNDR-E-MI-64194
MNDR hsa-miR-629-5p Small intestine cancer MNDR-E-MI-64195
MNDR hsa-miR-629-5p Prostate cancer MNDR-E-MI-64196
MNDR hsa-miR-629-5p Alzheimer disease MNDR-E-MI-64197
MNDR hsa-miR-629-5p Esophageal carcinoma MNDR-E-MI-64198
MNDR hsa-miR-629-5p Dysautonomia familial MNDR-E-MI-64199
MNDR hsa-miR-629-5p Leukemia MNDR-E-MI-64200
MNDR hsa-miR-629-5p Cardiovascular disease MNDR-E-MI-64201
MNDR hsa-miR-629-5p Lung cancer MNDR-E-MI-64202
MNDR hsa-miR-629-5p Down syndrome MNDR-E-MI-64203
MNDR hsa-miR-629-5p Parkinson disease MNDR-E-MI-64204
MNDR hsa-miR-629-5p Breast cancer MNDR-E-MI-64205
MNDR hsa-miR-629-5p Thyroid cancer MNDR-E-MI-64206
MNDR hsa-miR-629-5p Pituitary neoplasms MNDR-E-MI-64207
MNDR hsa-miR-629-5p Pancreatic cancer MNDR-E-MI-64208
MNDR hsa-miR-629-5p Melanoma MNDR-E-MI-64209
MNDR hsa-miR-629-5p Colon cancer MNDR-E-MI-64210
MNDR hsa-miR-629-5p Multiple sclerosis relapsing-remitting MNDR-E-MI-64211
MNDR hsa-miR-629-5p Familial ovarian cancer MNDR-E-MI-64212
MNDR hsa-miR-629-5p Acromegaly MNDR-E-MI-64213
MNDR hsa-miR-629-5p Prostate adenocarcinoma MNDR-E-MI-64214
MNDR hsa-miR-629-5p Carcinoma ductal breast MNDR-E-MI-64215
MNDR hsa-miR-629-5p Glioblastoma MNDR-E-MI-64216
MNDR hsa-miR-629-5p Glioma MNDR-E-MI-64217
MNDR hsa-miR-629-5p Amyotrophic lateral sclerosis MNDR-E-MI-64218
MNDR hsa-miR-629-5p Osteosarcoma MNDR-E-MI-64219
MNDR hsa-miR-629-5p Cervical squamous cell carcinoma MNDR-E-MI-64220
MNDR hsa-miR-629-5p Pituitary adenoma MNDR-E-MI-64221
MNDR hsa-miR-629-5p Lung squamous cell carcinoma MNDR-E-MI-64222
MNDR hsa-miR-629-5p Lung adenocarcinoma MNDR-E-MI-64223
MNDR hsa-miR-629-5p Thyroid carcinoma MNDR-E-MI-64224
MNDR hsa-miR-629-5p Bladder urothelial carcinoma MNDR-E-MI-64225
MNDR hsa-miR-629-5p Pancreatic adenocarcinoma MNDR-E-MI-64226
MNDR hsa-miR-629-5p Myasthenia gravis autoimmune experimental MNDR-E-MI-64227
MNDR hsa-miR-629-5p Carcinoma renal cell MNDR-E-MI-64228
MNDR hsa-miR-629-5p Kidney renal papillary cell carcinoma MNDR-E-MI-64229
MNDR hsa-miR-629-5p Clear cell renal cell carcinoma MNDR-E-MI-64230
MNDR hsa-miR-629-5p Biliary tract cancer MNDR-E-MI-64231
MNDR hsa-miR-629-5p Growth hormone-secreting pituitary adenoma MNDR-E-MI-64232
MNDR hsa-miR-629-5p Leukoencephalopathy progressive multifocal MNDR-E-MI-64233
MNDR hsa-miR-629-5p Breast invasive carcinoma MNDR-E-MI-64234
MNDR hsa-miR-629-5p Hepatocellular carcinoma MNDR-E-MI-64235
MNDR hsa-miR-629-5p Familiar ovarian carcinoma MNDR-E-MI-64236
MNDR hsa-miR-629-5p Barrett's adenocarcinoma MNDR-E-MI-64237
MNDR hsa-miR-629-5p Hodgkin lymphoma MNDR-E-MI-64238
MNDR hsa-miR-629-5p Ulcerative colitis MNDR-E-MI-64239
MNDR hsa-miR-629-5p Crohn disease MNDR-E-MI-64240
MNDR hsa-miR-629-5p Skin cutaneous melanoma MNDR-E-MI-64241
MNDR hsa-miR-629-5p Skin melanoma MNDR-E-MI-64242
MNDR hsa-miR-629-5p Acute myelocytic leukemia MNDR-E-MI-64243
MNDR hsa-miR-629-5p Colorectal cancer MNDR-E-MI-64244
MNDR hsa-miR-629-5p Nasopharynx carcinoma MNDR-E-MI-64245
MNDR hsa-miR-629-5p Nasopharyngeal cancer MNDR-E-MI-64246
MNDR hsa-miR-629-5p Epstein-barr virus infections MNDR-E-MI-64247
MNDR hsa-miR-629-5p Subarachnoid hemorrhage traumatic MNDR-E-MI-64248
MNDR hsa-miR-629-5p Chronic pain MNDR-E-MI-64249
MNDR hsa-miR-629-5p Stroke lacunar MNDR-E-MI-64250
MNDR hsa-miR-629-5p Barrett's carcinogenesis MNDR-E-MI-64251
MNDR hsa-miR-629-5p Breast cancer her3+ negative MNDR-E-MI-64252
MNDR hsa-miR-629-5p Solid-pseudopapillary neoplasm of pancreas MNDR-E-MI-64253
RNA Interaction Information
Resource RNA Symbol Species Link RNALocate ID
RNAInter HNF4A Homo sapiens RR00715562
TOP